Insider trade

Gilead Sciences (GILD): CEO sold ~$398K

Daniel Patrick O'day, CEO at Gilead Sciences, sold ~$398K of Gilead Sciences shares.

~$398K
Approx. value · 3,584 sh @ $110.96
620K
Holds after · shares reported
Traded
May 30, 2025
Filed
Jun 3, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Oct 29, 2024CongressDisclosed purchase of GILD — reported range $1,001 - $15,000
  2. Mar 7, 2025CongressDisclosed purchase of GILD — reported range $1,001 - $15,000
  3. Mar 10, 2025CongressDisclosed purchase of GILD — reported range $1,001 - $15,000
  4. Mar 31, 2025CongressDisclosed purchase of GILD — reported range $15,001 - $50,000
  5. Apr 15, 2025InsiderCFO sold ~$266K of GILD shares in the open market
  6. Apr 16, 2025CongressDisclosed sale of GILD — reported range $1,001 - $15,000
  7. May 5, 2025Congress · 1 personMembers of Congress: 3 purchases
  8. May 12, 2025CongressDisclosed sale of GILD — reported range $15,001 - $50,000
  9. May 14, 2025CongressDisclosed sale of GILD — reported range $1,001 - $15,000
  10. May 15, 2025InsiderCFO sold ~$250K of GILD shares in the open market
  11. May 22, 2025Insider · 1 personInsiders: 3 sales (~$3.0M)
  12. May 30, 2025 · this disclosureInsiderCEO sold ~$398K of GILD shares in the open market

What came next

  1. May 30, 2025InsiderCEO sold ~$706K of GILD shares in the open market
  2. Jun 6, 2025CongressDisclosed purchase of GILD — reported range $1,001 - $15,000
  3. Jun 16, 2025Insider · 2 peopleInsiders: 2 sales (~$606K)
  4. Jun 18, 2025FDAFDA drug approval: Yeztugo
  5. Jun 18, 2025FDAFDA drug approval: Yeztugo
  6. Jun 20, 2025FDAFDA drug approval: Tybost
  7. Jun 20, 2025FDAFDA drug approval: Tybost
  8. Jun 20, 2025FDAFDA drug approval: Descovy
  9. Jun 20, 2025FDAFDA drug approval: Descovy
  10. Jun 30, 2025Insider · 1 personInsiders: 2 sales (~$1.1M)
  11. Jul 14, 2025InsiderDirector sold ~$549K of GILD shares in the open market
  12. Jul 15, 2025Insider · 2 peopleInsiders: 2 sales (~$611K)
  13. Jul 28, 2025Insider · 1 personInsiders: 2 sales (~$1.1M)
  14. Jul 30, 2025FDAFDA drug approval: Biktarvy
  15. Aug 6, 2025Layoff notice · 4010 Ocean Ranch Blvd Oceanside CA 92056Layoff notice filed in CA: 5 employees
  16. Aug 15, 2025Insider · 2 peopleInsiders: 7 sales (~$3.6M)
  17. Aug 28, 2025InsiderCEO sold ~$1.14M of GILD shares in the open market
  18. Sep 15, 2025Insider · 2 peopleInsiders: 2 sales (~$625K)
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Gilead Sciences

For Gilead Sciences, OQRO holds 47 insider filings (SEC Form 4 or Form 144) and 1 fund holdings report (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its GILD page.

Other recent filings by Daniel Patrick O'day, Chairman & CEO

The full history of Daniel Patrick O'day, Chairman & CEO is on the profile page.

How this filing works

Explore the data

Common questions

Which Gilead Sciences (GILD) insider traded, and how much?

Daniel Patrick O'day, CEO at Gilead Sciences, sold ~$398K of Gilead Sciences shares. 3,584 shares at $110.96.

When did it happen, and when was it made public?

Traded: May 30, 2025. Filed: Jun 3, 2025. That is 4 days between the two dates.

Is the dollar amount exact?

It is the number of shares multiplied by the price the insider reported on the form. A grant, a gift or an option exercise has no market price, so those show shares only.

Where does this information come from?

From the SEC Form 4, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.

What else has been disclosed about Gilead Sciences recently?

For Gilead Sciences, OQRO holds 47 insider filings (SEC Form 4 or Form 144) and 1 fund holdings report (13F) dated in the last 90 days. They are listed on the GILD page.

Does this mean GILD stock is a buy or a sell?

No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.

Is OQRO free?

Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.

Other disclosures at Gilead Sciences

Everything OQRO holds on this company is on its GILD page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data